Erika Sloan from the global consulting firm CRA and Siddharth Arun discuss the future of innovation of CAR-T therapies in the solid tumor space and challenges t 15 December 2023
Kite, a subsidiary of US biotech major Gilead Sciences, has announced the results of new analyses supporting the use of Tecartus (brexucabtagene autoleucel) in 12 December 2023
At the 65th American Society of Hematology (ASH) annual meeting, Gilead Sciences company Kite has announced results from a three-year follow-up analysis of the 12 December 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.